Exchange & Returns Information
Review Details
(0)
| Drug Type | Original |
|---|---|
| Active Ingredient | IPILIMUMAB |
| Strength | 200MG |
| Manufacturer | BRISTOL MYERS SQUIBB |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 1 VIAL | $ 4,220.00 | $ 4,220.00 |
$ 3,587.00
Apply ZARVY26 (-15%)
You save $ 633.00
|
||
| 2 BOXES - 2 VIALS | $ 4,130.00 |
2% $ 8,440.00
$ 8,260.00
|
$ 7,021.00
Apply ZARVY26 (-15%)
You save $ 1,239.00
|
||
| ★ Best Value 3 BOXES - 3 VIALS | $ 3,990.00 |
5% $ 12,660.00
$ 11,970.00
|
$ 10,174.50
Apply ZARVY26 (-15%)
You save $ 1,795.50
|
Reference information will be available soon.
Yervoi 200mg, Solution for Injection is a high-dose formulation of Ipilimumab, an anti-CTLA-4 monoclonal antibody used as an immune checkpoint inhibitor. It enhances T-cell mediated antitumor responses by blocking CTLA-4, a negative regulator of T-cell activation. The 200 mg dose is commonly used in combination immunotherapy regimens, particularly with Nivolumab, to treat a wide range of advanced and metastatic cancers, including melanoma, NSCLC, RCC, hepatocellular carcinoma, and colorectal cancer. This formulation allows flexibility in adult and pediatric protocols requiring weight-based dosing across multiple cancer types.
AntiCancer Drugs > Skin Cancer (Melanoma)
Ipilimumab is a backbone agent in the treatment of advanced melanoma, used both as monotherapy and in combination with Nivolumab. It is also employed in adjuvant settings post-resection to reduce relapse risk in high-risk patients.
Lung Cancer (NSCLC, Mesothelioma)
Approved for metastatic NSCLC and malignant pleural mesothelioma in first-line combination regimens with chemotherapy and Nivolumab, especially in PD-L1 positive or high tumor burden cases.
Head and Neck Squamous Cell Carcinoma (HNSCC), Esophageal Cancer
Ipilimumab in combination with Nivolumab improves survival outcomes in recurrent or metastatic disease and PD-L1 positive cases, offering an immune-based alternative to platinum chemotherapy.
Liver Cancer (Hepatocellular Carcinoma)
Used for patients with HCC who progressed on or were intolerant to sorafenib. The combination immunotherapy offers durable disease control in select populations.
Kidney Cancer (Renal Cell Carcinoma)
First-line treatment for intermediate- and poor-risk advanced RCC in combination with Nivolumab, with survival advantage over sunitinib-based protocols.
Colorectal Cancer (MSI-H/dMMR)
Ipilimumab is approved with Nivolumab for microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancers that have failed prior chemotherapy.
Others (Pediatric Melanoma and CRC, Off-label uses)
Used in patients aged ≥12 years for melanoma and MSI-H colorectal cancer. Expanding off-label use includes refractory cancers where immune checkpoint blockade may provide benefit.
Melanoma (Adult): Monotherapy: 3 mg/kg IV every 3 weeks × 4 doses. Combo with Nivolumab: 3 mg/kg IV every 3 weeks × 4 doses. Adjuvant: 10 mg/kg IV every 3 weeks × 4 doses, then every 12 weeks up to 3 years. Infusion time: 30 minutes (standard), 90 minutes (adjuvant high dose).
Renal Cell Carcinoma (Adult): 1 mg/kg IV every 3 weeks × 4 doses (with Nivolumab 3 mg/kg).
Colorectal Cancer (MSI-H/dMMR, Adult): 1 mg/kg IV every 3 weeks × 4 doses (with Nivolumab 3 mg/kg).
Hepatocellular Carcinoma (Adult): 3 mg/kg IV every 3 weeks × 4 doses (with Nivolumab 1 mg/kg).
Non-Small Cell Lung Cancer (Adult): 1 mg/kg IV every 6 weeks (with Nivolumab 360 mg IV every 3 weeks), with 2 cycles platinum-doublet chemo.
Malignant Pleural Mesothelioma (Adult): 1 mg/kg IV every 6 weeks (with Nivolumab 360 mg IV every 3 weeks).
Esophageal Squamous Cell Carcinoma (Adult): 1 mg/kg IV every 6 weeks (with Nivolumab every 2 or 3 weeks).
Pediatric Melanoma (≥12 years): Monotherapy: 3 mg/kg IV every 3 weeks × 4 doses. Combo: 3 mg/kg IV every 3 weeks × 4 doses (with Nivolumab 1 mg/kg).
Pediatric Colorectal Cancer (≥12 years): 1 mg/kg IV every 3 weeks × 4 doses (with Nivolumab 3 mg/kg).
All infusions are administered over 30 minutes. Monitor for immune-related adverse effects, and adjust schedule accordingly. Nivolumab monotherapy is continued after Ipilimumab cycle completion unless toxicity occurs.
No reviews yet. Be the first to review this product!
No combo deals available at the moment.
